Compound News and Research

RSS

Preclinical safety data reports Natural S-equol has little effect on 2 reproductive hormones

Natural S-equol, a novel soy germ-based compound, is very likely the primary ingredient for reducing hot flushes in the dietary supplement SE5-OH, which is under development for reduction of menopause symptoms, according to pre-clinical efficacy data from studies using an animal model presented at the Experimental Biology 2010 annual meeting.

3 May 2010

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model.

30 Apr 2010

NovaBay to present data on Aganocide compounds at ARVO annual meeting

NovaBay Pharmaceuticals, Inc. announced today that the latest public data on its Aganocide® compounds, a new class of broad-spectrum antimicrobials, will be presented during three poster sessions at the Association for Research in Vision and Ophthalmology annual meeting in Fort Lauderdale, Florida.

30 Apr 2010

HemCon Medical Technologies to ask for reversal of jury verdict in chitosan patent case

HemCon Medical Technologies, Inc., announced today that it will ask a US District Court in New Hampshire to review and reverse a jury verdict based on a patent held by Marine Polymer Technologies, Inc. The jury awarded damages of $29.4 million against HemCon in the patent case. HemCon will ask the Court to review the validity of the patent and reverse the damage award.

30 Apr 2010

New tool to detect inflammatory eye disease at molecular level before damage occurs

Forget what you know about how diseases are diagnosed-new research published in the May 2010 print issue of The FASEB Journal details a noninvasive ground-breaking tool that detects signs of disease at early molecular stages before symptoms can be seen using traditional methods.

30 Apr 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 fiscal year (3QFY10).

30 Apr 2010

Study promises a new treatment for cancer

Cancer cells producing toxins that destroy tumours - could this be a future treatment for cancer? Researchers at Lund University have achieved good results in tests on both cells and animals.

30 Apr 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.

29 Apr 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

29 Apr 2010

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Albireo today announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation. A3309 is a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The results will be presented during the 2010 Digestive Disease Week (DDW) annual meeting being held in New Orleans, US.

29 Apr 2010

Bristol-Myers Squibb to present on belatacept at American Transplant Congress

Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of eight clinical presentations related to kidney transplantation at the American Transplant Congress, being held May 1 - 5 in San Diego.

29 Apr 2010

Fluorescent inhibitors hold promise for early-stage tumor detection

A series of novel imaging agents could light up tumors as they begin to form - before they turn deadly - and signal their transition to aggressive cancers.

29 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced that the company has made important progress, triggering a second tranche of $11 million in its Series A financing. Proceeds from the second tranche will be used to continue to advance Lycera's discovery and development efforts and further support the growth of the company.

29 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.

28 Apr 2010

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has published results from its Phase II GEMINI study in the Proceedings of the National Academy of Sciences (PNAS). These data, previously presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008, showed human proof of concept with an RNAi therapeutic in a randomized, double blind, placebo-controlled study.

27 Apr 2010

Study: Cigarette smoking, fructose consumption can worsen NAFLD

Recent studies suggest that modifiable risk factors such as cigarette smoking and fructose consumption can worsen nonalcoholic fatty liver disease. With NAFLD, fat accumulates in the liver of overweight individuals despite drinking little alcohol, causing in some cases liver scarring that can lead to liver failure.

27 Apr 2010

PPD confirms Japanese approval for Takeda's NESINA NDA

PPD, Inc. today confirmed that Takeda Pharmaceutical Company Limited's new drug application for NESINA® (alogliptin), a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare on April 16. PPD's compound partnering division collaborated with Takeda to develop this product.

27 Apr 2010

Compound News and Research

Preclinical safety data reports Natural S-equol has little effect on 2 reproductive hormones

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

NovaBay to present data on Aganocide compounds at ARVO annual meeting

HemCon Medical Technologies to ask for reversal of jury verdict in chitosan patent case

New tool to detect inflammatory eye disease at molecular level before damage occurs

Immunogen reports a net loss of $12.1 million in third quarter 2010

Study promises a new treatment for cancer

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Bristol-Myers Squibb to present on belatacept at American Transplant Congress

Fluorescent inhibitors hold promise for early-stage tumor detection

A new approach for treating neurological and degenerative disorders

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Study: Cigarette smoking, fructose consumption can worsen NAFLD

PPD confirms Japanese approval for Takeda's NESINA NDA

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News